|
September 12, 2023
|
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
|
|
|
September 12, 2023
|
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
|
|
|
August 24, 2023
|
Connect Biopharma to Participate in Upcoming September Investor Conferences
|
|
|
July 10, 2023
|
Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology
|
|
|
July 5, 2023
|
Connect Biopharma to Participate in the SVB Securities Therapeutics Forum
|
|
|
June 1, 2023
|
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
|
|
|
April 11, 2023
|
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
|
|
|
March 18, 2023
|
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
|
|
|
March 17, 2023
|
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
|
|
|
March 6, 2023
|
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
|
|
